GET IN TOUCH
Case Study

Commercial-Scale Chiral Resolution for Enhanced Yield and Optical Purity

Overview

Achieving high stereochemical purity while maintaining yield and scalability remains a common challenge in the development of chiral intermediates. Facing these challenges, a pharmaceutical innovator sought a robust chiral resolution strategy for a key intermediate that could consistently deliver high enantiomeric purity while supporting commercial-scale manufacturing. This case study highlights how Aragen developed and scaled an efficient resolution process to improve process performance and manufacturing readiness.

Challenges

Development of a commercially viable chiral process required addressing several technical challenges, including:

  • Achieving stringent optical purity specifications while maintaining acceptable process yields.
  • Developing a robust and reproducible resolution process suitable for large-scale manufacturing.
  • Optimizing crystallization and isolation parameters to maximize enantiomeric enrichment and product recovery.
  • Demonstrating process scalability while maintaining critical quality attributes (CQAs).
  • Ensuring uninterrupted GMP supply of the N-1 regulatory starting material to support manufacturing activities.

Aragen's Approach

Aragen developed a six-step synthetic route incorporating classical chiral resolution using (+)-2,3-dibenzoyl-D-tartaric acid as the resolving agent. As shown in Figure 1, the racemic intermediate was converted to a diastereomeric salt, enabling selective crystallization and isolation of the desired enantiomer with 99.9% pure.

Figure 1: Chiral resolution of the racemic intermediate using (+)-2,3-dibenzoyl-D-tartaric acid. Formation of a diastereomeric tartrate salt enabled stereoselective enrichment and isolation of the desired enantiomer. Optimization of salt formation, crystallization, and purification conditions resulted in >99.8% enantiomeric excess (ee) and successful scale-up to 100 kg manufacturing scale.

Process development efforts focused on optimizing solvent systems, crystallization conditions, and purification parameters to maximize stereoselectivity, product recovery, and process reproducibility. The optimized process consistently delivered the target enantiomer with high optical purity and was successfully scaled to 100 kg manufacturing scale.

In parallel, Aragen supplied 200 kg of GMP-grade N-1 regulatory starting material (RSM), ensuring uninterrupted program support. The integrated development and manufacturing approach enabled efficient scale-up while consistently meeting quality and enantiomeric purity specifications.

Outcomes

The optimized chiral resolution process was successfully demonstrated at 100 to 200 kg scale, establishing its suitability for commercial manufacturing. Key outcomes included:

  • Improved yield from 65% to 85%
  • Achieved >99.8% enantiomeric excess (ee)
  • Successfully executed chiral resolution at 100 to 200 kg scale
  • Supplied 200 kg of GMP-grade N-1 regulatory starting material
  • Demonstrated process robustness and commercial scalability

Conclusion

Through systematic process development and chiral resolution optimization, Aragen established a scalable and commercially viable manufacturing process for a stereochemically complex intermediate. The optimized route delivered a significant improvement in process yield while consistently achieving exceptional enantiomeric purity. Successful demonstration of the process at 100 kg scale, coupled with GMP supply of the key starting material, provided a robust foundation for future commercial manufacturing.

Why Aragen?

Aragen combines chiral resolution, asymmetric synthesis, and scale-up expertise to accelerate the development of complex chiral molecules. Our integrated capabilities span route design, stereoselective process development, purification, and cGMP manufacturing, enabling efficient progression from lab scale to commercial production.

  • Broad chiral toolbox: Chemical resolution, enzymatic approaches, solubility-based separation, and SFC purification.
  • Advanced synthesis expertise: Metal-catalyzed, chiral auxiliary-, and enzyme-mediated transformations.
  • Proven scale-up capability: Seamless transition from development to multi-kilogram and commercial-scale manufacturing.
  • Integrated execution: Development, scale-up, and manufacturing under one roof.

Facing a complex chirality challenge? Partner with Aragen to develop robust, scalable processes that deliver high purity and manufacturing readiness.